These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 30035825)

  • 1. Treatment outcomes in patients with proven/probable vs possible invasive mould disease in a phase III trial comparing isavuconazole vs voriconazole.
    Maertens J; Selleslag D; Heinz WJ; Saulay M; Rahav G; Giladi M; Aoun M; Kovanda L; Kaufhold A; Engelhardt M; Cornely OA; Herbrecht R; Ullmann AJ
    Mycoses; 2018 Nov; 61(11):868-876. PubMed ID: 30035825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial.
    Maertens JA; Raad II; Marr KA; Patterson TF; Kontoyiannis DP; Cornely OA; Bow EJ; Rahav G; Neofytos D; Aoun M; Baddley JW; Giladi M; Heinz WJ; Herbrecht R; Hope W; Karthaus M; Lee DG; Lortholary O; Morrison VA; Oren I; Selleslag D; Shoham S; Thompson GR; Lee M; Maher RM; Schmitt-Hoffmann AH; Zeiher B; Ullmann AJ
    Lancet; 2016 Feb; 387(10020):760-9. PubMed ID: 26684607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isavuconazole for treatment of invasive fungal diseases caused by more than one fungal species.
    Marty FM; Cornely OA; Mullane KM; Ostrosky-Zeichner L; Maher RM; Croos-Dabrera R; Lu Q; Lademacher C; Oren I; Schmitt-Hoffmann AH; Giladi M; Rahav G; Perfect JR
    Mycoses; 2018 Jul; 61(7):485-497. PubMed ID: 29611227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isavuconazole for treatment of rare invasive fungal diseases.
    Cornely OA; Mullane KM; Ostrosky-Zeichner L; Maher RM; Croos-Dabrera R; Lu Q; Lademacher C; Perfect JR; Oren I; Schmitt-Hoffmann AH; Giladi M; Marty FM; Rahav G
    Mycoses; 2018 Aug; 61(8):518-533. PubMed ID: 29611246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hospital resource use of patients receiving isavuconazole vs voriconazole for invasive mold infections in the phase III SECURE trial.
    Horn D; Goff D; Khandelwal N; Spalding J; Azie N; Shi F; Franks B; Shorr AF
    J Med Econ; 2016 Jul; 19(7):728-34. PubMed ID: 26960060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of unresolved neutropenia in patients with neutropenia and invasive aspergillosis: a post hoc analysis of the SECURE trial.
    Kontoyiannis DP; Selleslag D; Mullane K; Cornely OA; Hope W; Lortholary O; Croos-Dabrera R; Lademacher C; Engelhardt M; Patterson TF
    J Antimicrob Chemother; 2018 Mar; 73(3):757-763. PubMed ID: 29194488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isavuconazole and voriconazole for the treatment of chronic pulmonary aspergillosis: A retrospective comparison of rates of adverse events.
    Bongomin F; Maguire N; Moore CB; Felton T; Rautemaa-Richardson R
    Mycoses; 2019 Mar; 62(3):217-222. PubMed ID: 30570179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic review and network meta-analysis of clinical outcomes associated with isavuconazole versus relevant comparators for patients with invasive aspergillosis.
    Herbrecht R; Kuessner D; Pooley N; Posthumus J; Escrig C
    Curr Med Res Opin; 2018 Dec; 34(12):2187-2195. PubMed ID: 30022696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post-hoc analysis of the safety and efficacy of isavuconazole in older patients with invasive fungal disease from the VITAL and SECURE studies.
    Hamed K; Engelhardt M; Kovanda LL; Huang JJ; Yan J; Aram JA
    Sci Rep; 2023 Apr; 13(1):6730. PubMed ID: 37185921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-life use of isavuconazole outside the hematological wards.
    Scabini S; Lupia T; Angilletta R; De Rosa FG; Corcione S
    Eur J Intern Med; 2019 Dec; 70():e10-e12. PubMed ID: 31526649
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical experience with isavuconazole in healthy volunteers and patients with invasive aspergillosis in China, and the results from an exposure-response analysis.
    Zhang J; Zhang Y; Wu D; Cao G; Hamed K; Desai A; Aram JA; Guo X; Fayyad R; Cornely OA
    Mycoses; 2021 Apr; 64(4):445-456. PubMed ID: 33355949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of triazoles for the treatment of invasive aspergillosis: A three-year cohort analysis.
    Cheng MP; Orejas JL; Arbona-Haddad E; Bold TD; Solomon IH; Chen K; Pandit A; Kusztos AE; Cummins KC; Liakos A; Marty FM; Koo S; Hammond SP
    Mycoses; 2020 Jan; 63(1):58-64. PubMed ID: 31587405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: Challenges and lessons of the VITAL trial.
    Perfect JR; Cornely OA; Heep M; Ostrosky-Zeichner L; Mullane KM; Maher R; Croos-Dabrera R; Lademacher C; Engelhardt M; Chen C; Marty FM
    Mycoses; 2018 Jul; 61(7):420-429. PubMed ID: 29570857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Pharmacokinetics and Pharmacodynamics of Isavuconazole.
    McCarthy MW; Moriyama B; Petraitiene R; Walsh TJ; Petraitis V
    Clin Pharmacokinet; 2018 Dec; 57(12):1483-1491. PubMed ID: 29725999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing the safety and efficacy of voriconazole versus posaconazole in the prevention of invasive fungal infections in high-risk patients with hematological malignancies.
    Hachem R; Assaf A; Numan Y; Shah P; Jiang Y; Chaftari AM; Raad II
    Int J Antimicrob Agents; 2017 Sep; 50(3):384-388. PubMed ID: 28694233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New pharmacological opportunities for the treatment of invasive mould diseases.
    Ledoux MP; Toussaint E; Denis J; Herbrecht R
    J Antimicrob Chemother; 2017 Mar; 72(suppl_1):i48-i58. PubMed ID: 28355467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial.
    Maertens JA; Rahav G; Lee DG; Ponce-de-León A; Ramírez Sánchez IC; Klimko N; Sonet A; Haider S; Diego Vélez J; Raad I; Koh LP; Karthaus M; Zhou J; Ben-Ami R; Motyl MR; Han S; Grandhi A; Waskin H;
    Lancet; 2021 Feb; 397(10273):499-509. PubMed ID: 33549194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variability and exposure-response relationships of isavuconazole plasma concentrations in the Phase 3 SECURE trial of patients with invasive mould diseases.
    Kaindl T; Andes D; Engelhardt M; Saulay M; Larger P; Groll AH
    J Antimicrob Chemother; 2019 Mar; 74(3):761-767. PubMed ID: 30476108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isavuconazole shortens the QTc interval.
    Mellinghoff SC; Bassetti M; Dörfel D; Hagel S; Lehners N; Plis A; Schalk E; Vena A; Cornely OA
    Mycoses; 2018 Apr; 61(4):256-260. PubMed ID: 29178247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world challenges and unmet needs in the diagnosis and treatment of suspected invasive pulmonary aspergillosis in patients with haematological diseases: An illustrative case study.
    Hoenigl M; Prattes J; Neumeister P; Wölfler A; Krause R
    Mycoses; 2018 Mar; 61(3):201-205. PubMed ID: 29112326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.